A clinical expert panel from the Sjögren's Syndrome Foundation has published the first-ever clinical practice guidelines for the disease in the United States.
After 3-month extension to review, regulator says NDA for baricitinib cannot be approved in its current form.
Psoriatic arthritis, patient weight, registration country and more influence first-line biologic treatment selection for patients with psoriasis.
Jonathan Krant, MD, FACP, confronts the issues surrounding biosimilar substitution for biologic treatments.
Investigators conduct a systematic review to evaluate the risks and benefits of biologics as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis who have not responded to previous biologic treatment.
WCO 2017, FDA grants Rituxan Breakthrough Therapy status, and a close-up of pediatric Sjögren's syndrome highlight this week's The Handoff.
FDA gives breakthrough therapy designation to rituxan for treatment of pemphigus vulgaris and is indicated for treating rheumatoid arthritis
Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Study examined patients with active rheumatoid arthritis who failed to derive benefit from or were intolerant to TNF-inhibitor therapy.
Connecticut considers rheumatoid arthritis and fibromyalgia for medical marijuana treatment, while Lyme disease-carrying deer ticks continue to invade Michigan. All this and more in this week's edition.
Phase 3 trial in patients taking baricitinib, adalimumab, or placebo in addition to methotrexate background therapy.
Most patients with psoriasis who were withdrawn from ixekizumab therapy experienced disease relapse.
Prospective observational study yields patients with hepatitis B reactivation, but all were asymptomatic.
Study finds weak evidence for using biomarkers as a guide to tapering or discontinuing biologic therapy in patients with rheumatoid arthritis.
Rituximab significantly reduces mean DAS28 scores in patients with rheumatoid arthritis after retreatment cycles.
Regulator advises use of unique suffix system to identify each biological product and biosimilars.
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
The likelihood of regaining ability to work was studied in patients with rheumatoid arthritis who initiated anti-tumor necrosis factor therapy within 5 years.
Data show biologics may help with comorbid cardiovascular disease conditions, but more studies are needed regarding their impact on depression, gastrointestinal disease, and osteoporosis.
High exclusion rates were associated with RCTs conducted over short periods of time, resulting in necessary caution when applying study results to daily clinical practice.
Data from a recent study show under-utilization of MTX before initiating biologic therapies in patients with RA.
The US Food and Drug Administration (FDA) has accepted Genentech's Biologics License Application for a subcutaneous formulation of rituximab.
This video discusses issues related to insurance coverage and therapeutic substitution of biologic biosimilars.
Data from a large German cohort found a greater risk for lower intestinal perforation with tocilizumab as compared with conventional synthetic disease-modifying antirheumatic drug therapy for rheumatoid arthritis (RA).
A recent clinical report published in Pediatrics confirms the real-world increased risk of infectious complications associated with biologic response modifiers.
Post-hoc analysis of the FUTURE-2 trial was performed to assess if there was a differential treatment responses to secukinumab in TNFi-exposed or naïve patients with active psoriatic arthritis.
Results of 2 clinical trials suggest that etanercept monotherapy and etanercept-methotrexate combination therapy may confer similar benefits in the treatment of psoriatic arthritis.
CT-P13 is highly similar to infliximab (Remicade), with no noted clinical differences in safety, purity, or potency.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care